Hamilton Lane Advisors’s Acceleron Pharma XLRN Stock Holding History

Hamilton Lane Advisors’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-69,503	Closed	-$2.95M	–	57
2017 Q4	$2.95M	Sell	69,503 -5,487	-7%	-$206K	1.52%	19
2017 Q3	$2.8M	Sell	74,990 -8,000	-10%	-$278K	1.92%	12
2017 Q2	$2.52M	Sell	82,990 -10,000	-11%	-$290K	1.38%	19
2017 Q1	$2.46M	Hold	92,990	–	–	1.24%	22
2016 Q4	$2.37M	Buy	92,990 +59,650	+179%	+$1.89M	1.56%	19
2016 Q3	$1.21M	Hold	33,340	–	–	0.61%	35
2016 Q2	$1.14M	Sell	33,340 -4,064	-11%	-$132K	0.55%	34
2016 Q1	$987K	Sell	37,404 -4,488	-11%	-$131K	0.47%	34
2015 Q4	$2.04M	Sell	41,892 -571	-1%	-$20.5K	0.9%	24
2015 Q3	$1.06M	Hold	42,463	–	–	0.52%	32
2015 Q2	$1.34M	Buy	42,463 +19,816	+87%	+$639K	0.51%	35
2015 Q1	$862K	Sell	22,647 -19,902	-47%	-$791K	0.39%	31
2014 Q4	$1.66M	Buy	+42,549	New	+$1.48M	0.63%	28
2014 Q2	–	Sell	-9,805	Closed	-$338K	–	72
2014 Q1	$338K	Buy	+9,805	New	+$442K	0.14%	57

Other funds holding XLRN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Hamilton Lane Advisors's XLRN Position: Q1 2018 in Review

Hamilton Lane Advisors sold out of Acceleron Pharma (XLRN) in Q1 2018, closing a stake of 69,503 shares — an estimated $2.95M sold.

Hamilton Lane Advisors first reported a position in XLRN in Q1 2014 and held it in 14 quarters. The position peaked at $2.95M in Q4 2017. 150 funds tracked by Wall St. Rank hold XLRN as of Q1 2018.

Hamilton Lane Advisors reported no remaining Acceleron Pharma position as of Q1 2018 after selling out during the quarter.
Hamilton Lane Advisors sold 69,503 Acceleron Pharma shares in Q1 2018, an estimated $2.95M.
Hamilton Lane Advisors first reported a position in Acceleron Pharma in Q1 2014 and held it in 14 quarters.
Hamilton Lane Advisors's Acceleron Pharma position peaked at $2.95M in Q4 2017.
150 funds tracked by Wall St. Rank held Acceleron Pharma as of Q1 2018.

Based on Hamilton Lane Advisors's 13F filing for Q1 2018, filed 3 May 2018.